本文選題：冠心病 + 荷丹片�。� 參考：《遼寧中醫(yī)雜志》2017年05期

【摘要】：目的:觀察荷丹片聯(lián)合阿托伐他汀治療冠心病的臨床治療效果以其為臨床診療提供參考。方法:分析2015年1月—2016年1月在我院接受診療的冠心病(穩(wěn)定性心絞痛)患者的資料。依據(jù)治療藥物的不同將患者分為觀察組(阿托伐他汀+荷丹片)及對(duì)照組(阿托伐他汀)。對(duì)比兩組患者治療期12個(gè)月內(nèi)心絞痛的累積發(fā)生率并檢測(cè)相關(guān)血液學(xué)指標(biāo)的改變。結(jié)果:本研究共納入觀察組41例,對(duì)照組44例。觀察組治療期間心絞痛的累積發(fā)生率顯著低于對(duì)照組(14.63%,6/41 vs 36.36%,16/44;Log-rankχ~2=5.619,P=0.018)。治療后,觀察組與對(duì)照組TC、TG、LDL-c水平均顯著降低(P0.05),但觀察組低于對(duì)照組患者(P0.05)。治療后,兩組患者治療后HDL-c水平均顯著升高(P0.05),但觀察組高于對(duì)照組患者(P0.05)。治療后,觀察組與對(duì)照組CRP、MMP-1、PAPP-A水平均顯著降低(P0.05),但觀察組低于對(duì)照組患者(P0.05)。結(jié)論:聯(lián)合使用荷丹片可顯著降低冠心病患者心絞痛發(fā)作頻率,可能與其調(diào)控血脂、抗炎及提高動(dòng)脈粥樣斑塊穩(wěn)定等療效有關(guān)。
[Abstract]:Objective: to observe the clinical effect of Hedan tablet combined with Atto vastatin in the treatment of coronary heart disease. Methods: the data of patients with coronary heart disease (stable angina pectoris) treated in our hospital from January 2015 to January 2016 were analyzed. Patients were divided into observation group (Atto vastatin Hedan tablet) and control group (Atto vastatin). The cumulative incidence of angina pectoris and the changes of related hematologic indexes were compared between the two groups during 12 months. Results: the study included 41 cases in the observation group and 44 cases in the control group. The cumulative incidence of angina pectoris in the observation group was significantly lower than that in the control group (14.63 / 6 / 41 vs 36.36) during the treatment period. After treatment, the levels of TCU TGN LDL-c in both the observation group and the control group were significantly decreased, but the levels in the observation group were lower than those in the control group. After treatment, the level of HDL-c in the two groups was significantly higher than that in the control group, but the level of HDL-c in the observation group was higher than that in the control group. After treatment, the levels of MMP-1 and PAPP-A in the observation group and the control group decreased significantly, but the levels in the observation group were lower than those in the control group. Conclusion: combined use of Hedan tablet can significantly reduce the frequency of angina pectoris attack in patients with coronary heart disease, which may be related to its effect on regulating blood lipid, anti-inflammation and improving the stability of atherosclerotic plaque.
【作者單位】： 濟(jì)寧學(xué)院醫(yī)院;山東巨野煤田中心醫(yī)院;
【分類(lèi)號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前2條

1 楊錫珍;楊國(guó)亮;苗少輝;徐洋;尹冬梅;;超聲評(píng)價(jià)荷丹片聯(lián)合阿托伐他汀治療頸動(dòng)脈粥樣硬化的療效[J];河北醫(yī)藥;2013年18期

2 ;[J];;年期

，

本文編號(hào)：1945482